Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Ariana P. Vargas-Delgado"'
Autor:
Ariana P. Vargas-Delgado, Estefania Arteaga Herrera, Cesar Tumbaco Mite, Patricia Delgado Cedeno, Maria Cristina Van Loon, Juan J. Badimon
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 4, p 4144 (2023)
Sodium–glucose cotransporter type 2 inhibitors (SGLT2i) are glycosuric drugs that were originally developed for the treatment of type 2 diabetes mellitus (T2DM). There is a hypothesis that SGLT2i are drugs that are capable of increasing ketone bodi
Externí odkaz:
https://doaj.org/article/711128b86f2941f081700cd2b1ddc6d6
Publikováno v:
International Journal of Molecular Sciences, Vol 20, Iss 13, p 3289 (2019)
The sodium-glucose cotransporter (SGLT) inhibitors represent a new alternative for treating patients with diabetes mellitus. They act primarily by inhibiting glucose reabsorption in the renal tubule and therefore, decreasing blood glucose levels. Whi
Externí odkaz:
https://doaj.org/article/0c3b99f099464b33a5182829b4f68435
Autor:
Anderly Rodriguez-Cordero, Valentin Fuster, Ariana P. Vargas-Delgado, Chiara Giannarelli, Javier Sanz, Juan J. Badimon, Frank Macaluso, Farah Atallah-Lajam, Donna M. Mancini, Juan Antonio Requena-Ibanez, Anuradha Lala, Samantha Sartori, Carlos G. Santos-Gallego
Publikováno v:
JACC: Heart Failure. 9:578-589
Objectives The goal of this study was to evaluate the effect of empagliflozin, in addition to optimal medical treatment, on epicardial adipose tissue (EAT), interstitial myocardial fibrosis, and aortic stiffness in nondiabetic patients with heart fai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b032c45173c4d68c3303aa43c2c905c2
https://doi.org/10.1016/j.jchf.2021.04.014
https://doi.org/10.1016/j.jchf.2021.04.014
Autor:
Carlos G. Santos-Gallego, Juan J. Badimon, Juan Antonio Requena Ibanez, Ariana P. Vargas Delgado
Publikováno v:
Clínica e Investigación en Arteriosclerosis. 33:33-40
Resumen Los inhibidores del cotransportador de sodio-glucosa tipo 2 (iSGLT2) fueron incialmente desarrollados para el tratamiento de la diabetes por su actividad hipoglucemiante. Sin embargo, a la luz de los estudios clinicos mas recientes, estan rev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::29908927e9540a9f9d3ff61675205dfe
https://doi.org/10.1016/j.arteri.2020.08.001
https://doi.org/10.1016/j.arteri.2020.08.001
Autor:
Anuradha Lala, Sean Pinney, Empa-Tropism (Atru ) Investigators, M. Urooj Zafar, Alvaro Garcia-Ropero, Javier Sanz, Icilma V. Fergus, Juan J. Badimon, Carlos G. Santos-Gallego, Vivian M. Abascal, Valentin Fuster, Juan Antonio Requena-Ibanez, Mercè Roqué, Donna M. Mancini, Ariana P. Vargas-Delgado, Ronald Tamler, Pedro R. Moreno, Fernando Sabatel-Perez, Farah Atallah-Lajam, Frank Macaluso, Cathleen Varley, Samantha Sartori, Johanna Contreras, Anderly Rodriguez-Cordero
Publikováno v:
Journal of the American College of Cardiology. 77:243-255
Large clinical trials established the benefits of sodium-glucose cotransporter 2 inhibitors in patients with diabetes and with heart failure with reduced ejection fraction (HFrEF). The early and significant improvement in clinical outcomes is likely
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c9da2adf6daab5cd4bd3b6863519f5f
https://doi.org/10.1016/j.jacc.2020.11.008
https://doi.org/10.1016/j.jacc.2020.11.008
Autor:
Ariana P. Vargas Delgado, Juan Antonio Requena Ibanez, Juan J. Badimon, Carlos G. Santos-Gallego
Publikováno v:
Clínica e Investigación en Arteriosclerosis (English Edition). 33:33-40
The sodium-glucose co-transporter 2 inhibitors (SGLT2i) were first conceived to treat type 2 diabetes due to their hypoglycaemic effect. However, due to an increasing number of studies, SGLT2i are changing the way we treat, and understand, diabetes,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be4d288973976f58b0c2f8db9be525d1
https://doi.org/10.1016/j.artere.2020.12.004
https://doi.org/10.1016/j.artere.2020.12.004
Publikováno v:
Journal of Cardiovascular Pharmacology. 75:269-275
Long-standing aspirin is the cornerstone to prevent recurrence of thrombotic events in patients with ischemic heart disease. However, clopidogrel, a more potent antiplatelet agent, is preferred over aspirin in targeted populations, including those wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f3b26f41973b52cd9d1201a3dca4dee
https://doi.org/10.1097/fjc.0000000000000795
https://doi.org/10.1097/fjc.0000000000000795
Autor:
Juan Antonio, Requena-Ibáñez, Carlos G, Santos-Gallego, Anderly, Rodriguez-Cordero, Ariana P, Vargas-Delgado, Donna, Mancini, Samantha, Sartori, Farah, Atallah-Lajam, Chiara, Giannarelli, Frank, Macaluso, Anuradha, Lala, Javier, Sanz, Valentin, Fuster, Juan José, Badimon
Publikováno v:
JACC. Heart failure. 9(8)
The goal of this study was to evaluate the effect of empagliflozin, in addition to optimal medical treatment, on epicardial adipose tissue (EAT), interstitial myocardial fibrosis, and aortic stiffness in nondiabetic patients with heart failure with r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e55a380764229b18bdaea268d03f55fc
https://pubmed.ncbi.nlm.nih.gov/34325889
https://pubmed.ncbi.nlm.nih.gov/34325889
Autor:
Ariana P, Vargas Delgado, Juan Antonio, Requena Ibañez, Carlos G, Santos-Gallego, Juan Jose, Badimon
Publikováno v:
Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.
The sodium-glucose co-transporter 2 inhibitors (SGLT2i) were first conceived to treat type 2 diabetes due to their hypoglycaemic effect. However, due to an increasing number of studies, SGLT2i are changing the way we treat, and understand, diabetes,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2b797c4d2f880732cb079eaea5d3d258
https://pubmed.ncbi.nlm.nih.gov/34756346
https://pubmed.ncbi.nlm.nih.gov/34756346
Autor:
Juan Antonio Requena-Ibanez, Kiyotake Ishikawa, Alvaro Garcia-Ropero, Ariana P. Vargas-Delgado, Belén Picatoste, José Tuñón, Carlos G. Santos-Gallego, Javier Sanz, Juan J. Badimon
The sodium-glucose cotransporter type 2 inhibitors reduce mortality and heart failure (HF) hospitalizations. The underlying mechanisms remain unclear but seem to be irrespective of glucose-lowering properties. This study aims to evaluate the impact o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2505bb704da0be7a545142bd387c5334
